ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
ALX Oncology (Nasdaq: ALXO) announced that Jaume Pons, Ph.D., its CEO, will present a company overview at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) announced that Jaume Pons, Ph.D., its CEO, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 10:50 am ET. The presentation will be accessible via a live webcast, available on the Investors section of ALX Oncology’s website. Following the event, a replay of the webcast will be archived for 30 days. ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promise in treating various cancers.
Details
News Market Reaction – ALXO
The recorded move for ALXO in the trading session of this news was +6.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 10:50 am ET.
A live webcast of the presentation is available here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology’s website at www.alxoncology.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.